Abbvie Inc (ABBV)

$257.12 +2.12 (0.83%)
Market Cap 450.53B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.08
Forward PE 17.85
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 4,308,800
Avg Vol 5,209,052
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 59%
Beta 0.29
Analysts Strong Sell
Price Target $277.87

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 4:04 AM
$SLS $MRNA $ABBV TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 3:50 AM
$SLS $ABBV 19 Month MOS for CR1 First Remission on BAT - is actually just 17.3 months when equalized for the time in treatment vs from Enrollment in REGAL. Any way you look at it 19 or 17 months In CR1 translates to 8 or 9 months MOS in Second Remission CR2 - just like all the doctors treating Regal patients are saying and the same as the Avalon 8.8 month MOS. https://haematologica.org/article/view/14308
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:51 PM
$SLS $ABBV We Know from the IDMC Unblinded ACTUAL Phase 3 MOS and Median Follow up Data from the Interim Analysis: • Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:45 PM
$SLS $ABBV For the Inch Thick Mile Wide Short Lowlife -- only. Can you explain the implications of the VIALE-M and VIALE-T Phase 3 Trial FAILURES? VIALE-M Phase 3 Combining Oral Az+VEN FAILED for AML FIRST REMISSION MAINTENANCE - BAT for the SLS P3 Control ARM Patients in Second Remission FAILED a Phase 3 For First Remission Maintenance -- Explain....
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:17 PM
$SLS $MRNA $ABBV BAT for the SLS P3 Control ARM/ Onureg +VEN Failed in First Remission (CR1) VIALE-M FAILED. Onureg - as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. We Know from the IDMC Unblinded P3 MOS and Median Follow up data ... Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. it is not complicated
0 · Reply
parcha
parcha Sep. 11 at 10:01 PM
$ABBV Investment bank Wells Fargo set a 12-month price target for pharmaceutical company AbbVie of $300 on Thursday, giving the Chicago-based company an overweight rating, which is equivalent to a buy. Analyst Mohit Bansal said the AbbVie has solid patent protection for its core business units and that he is expecting updates on the firm’s work in oncology and neuroscience. “We rate ABBV Overweight, as we think that the stock is reasonably priced for strong growth into the next decade, coupled with long-term patent protection for key businesses. We expect mid-stage pipeline to come to limelight in next 12 months, which should help with multiple expansion,” https://www.cnbc.com/2026/09/10/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:07 PM
$SLS $MRNA $ABBV BAT / Onureg +VEN Failed in First Remission (CR1) Onureg as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:02 PM
$SLS $ABBV Onureg / Oral Aza MOS is 24.7 months ADDING VEN did not increase Survival
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:39 PM
$SLS $MRNA $ABBV added Venetoclax to Onureg for First Remission Patients in the VIALE-M Trial. Onureg / Oral Aza MOS is 24.7 months ADDING VEN did not increase Survival Gps Phase 3 MOS - in the ONGOING P3 will come in 34/36 Months ... Gps Phase 3 CR2 MOS - in the ONGOING P3 will come in 34/36 Months ... Longer MOS in CR2 than SOC in CR1... GPs Phase 2 MOS in CR1 was 67.6 Months GPS Phase 2 MOS in CR2 was 21 months - an older, Less Healthy all MRD+ setting, with less Gps Dosing.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:33 PM
$SLS $MRNA $ABBV DOES EVERYONE KNOW -- BAT for the SLS P3 CONTROL ARM - FAILED 3 Large Phase 3 Trials ????? FULL TITLE: Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) FAILED ... FAILED the Control ARM Second Remission Patients in the SLS REGAL Phase 3 Trial Too....
0 · Reply
Latest News on ABBV
No data available.
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 4:04 AM
$SLS $MRNA $ABBV TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 3:50 AM
$SLS $ABBV 19 Month MOS for CR1 First Remission on BAT - is actually just 17.3 months when equalized for the time in treatment vs from Enrollment in REGAL. Any way you look at it 19 or 17 months In CR1 translates to 8 or 9 months MOS in Second Remission CR2 - just like all the doctors treating Regal patients are saying and the same as the Avalon 8.8 month MOS. https://haematologica.org/article/view/14308
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:51 PM
$SLS $ABBV We Know from the IDMC Unblinded ACTUAL Phase 3 MOS and Median Follow up Data from the Interim Analysis: • Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:45 PM
$SLS $ABBV For the Inch Thick Mile Wide Short Lowlife -- only. Can you explain the implications of the VIALE-M and VIALE-T Phase 3 Trial FAILURES? VIALE-M Phase 3 Combining Oral Az+VEN FAILED for AML FIRST REMISSION MAINTENANCE - BAT for the SLS P3 Control ARM Patients in Second Remission FAILED a Phase 3 For First Remission Maintenance -- Explain....
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:17 PM
$SLS $MRNA $ABBV BAT for the SLS P3 Control ARM/ Onureg +VEN Failed in First Remission (CR1) VIALE-M FAILED. Onureg - as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. We Know from the IDMC Unblinded P3 MOS and Median Follow up data ... Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. it is not complicated
0 · Reply
parcha
parcha Sep. 11 at 10:01 PM
$ABBV Investment bank Wells Fargo set a 12-month price target for pharmaceutical company AbbVie of $300 on Thursday, giving the Chicago-based company an overweight rating, which is equivalent to a buy. Analyst Mohit Bansal said the AbbVie has solid patent protection for its core business units and that he is expecting updates on the firm’s work in oncology and neuroscience. “We rate ABBV Overweight, as we think that the stock is reasonably priced for strong growth into the next decade, coupled with long-term patent protection for key businesses. We expect mid-stage pipeline to come to limelight in next 12 months, which should help with multiple expansion,” https://www.cnbc.com/2026/09/10/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:07 PM
$SLS $MRNA $ABBV BAT / Onureg +VEN Failed in First Remission (CR1) Onureg as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:02 PM
$SLS $ABBV Onureg / Oral Aza MOS is 24.7 months ADDING VEN did not increase Survival
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:39 PM
$SLS $MRNA $ABBV added Venetoclax to Onureg for First Remission Patients in the VIALE-M Trial. Onureg / Oral Aza MOS is 24.7 months ADDING VEN did not increase Survival Gps Phase 3 MOS - in the ONGOING P3 will come in 34/36 Months ... Gps Phase 3 CR2 MOS - in the ONGOING P3 will come in 34/36 Months ... Longer MOS in CR2 than SOC in CR1... GPs Phase 2 MOS in CR1 was 67.6 Months GPS Phase 2 MOS in CR2 was 21 months - an older, Less Healthy all MRD+ setting, with less Gps Dosing.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:33 PM
$SLS $MRNA $ABBV DOES EVERYONE KNOW -- BAT for the SLS P3 CONTROL ARM - FAILED 3 Large Phase 3 Trials ????? FULL TITLE: Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) FAILED ... FAILED the Control ARM Second Remission Patients in the SLS REGAL Phase 3 Trial Too....
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:19 PM
$SLS $MRNA $ABBV ABBVIE INVESTIGATIONAL PRODUCT: Venetoclax (ABT-199) EU CT: FULL TITLE: Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) FAILED ... FAILED the Control ARM in the SLS REGAL Phase 3 Trial Too....
0 · Reply
quezoitm
quezoitm Sep. 11 at 7:18 PM
$ABBV $MRNA $SLS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:17 PM
$SLS $MRNA $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 6:29 PM
$SLS With all the FUD... Yes Best Available Treatment BAT for Control Patients - Aza+VEN - FAILED 3 Large Phase 3 Trials conducted by $ABBV VIALE-T FAILED for Post Transplant Maintenance VIALE-M Failed for AML FIRST REMISSION Maintenance Aza+VEN is Failing for AML SECOND Remission Maintenance too. its even more toxic and ineffective in the Later Stage. They TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 5:43 PM
$SLS $MRNA Onureg / Oral Az / Aza is the Standard of Care for AML First Remission Patients (CR1) - Median Overall Survival 24.7 Months. Gps Phase 2 MOS for the same exact First Remission (CR1) setting was not reached and GREATER Than > 67.6 months. Onureg / SOC 24.7 Gps > 67.6 Onureg was combined with Venetoclax in the VIALE-M Phase 3 trial conducted by $ABBV for AML First Remission (CR1) Patients - the MOS is unkwown because the TRIAL FAILED. VIALE-T Phase 3 for AML Post Transplant Maintenance also - FAILED.
0 · Reply
StochAlpha
StochAlpha Sep. 11 at 11:16 AM
Top 5 Buys · Sep 11, 2026 $FROG and $ROKU both showing RS and institutional scores in the 85-90 range. $ABBV quietly sitting at institutional accumulation of 89 — institutions have been loading this one for some time now. Diverse group today. The scan follows the setup, not the sector.
0 · Reply
Mantraset3
Mantraset3 Sep. 11 at 5:10 AM
$ABBV Botox makes everything better 💰
0 · Reply
Gebinator
Gebinator Sep. 10 at 9:13 PM
$SLS $JNJ $MRK there we have it -- $ABBV wins the potential 'spoiler' award according to 39% of 104 poll respondents --thanks! Whether some transaction for SLS009 to pair with Venclexta or the whole enchilada with GPS, it appears $ABBV is still a contender to take some or all 🏆 Pfizer not too far behind at 31% and Lilly keeping its 'dark horse' status with about a quarter of the vote (24%). Meanwhile, AstraZeneca far behind (6%). Are there more 'dark horses' still in the running? ...
0 · Reply
focafoca99
focafoca99 Sep. 10 at 6:41 PM
$ABBV established a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. https://www.rapidticker.com/news/abbv-abbvie-declares-quarterly-dividend-fe7d37
0 · Reply
DidYouReadThis
DidYouReadThis Sep. 10 at 5:36 PM
$NVS $COR $LLY $ABBV #commercialization #advertising When you think of memorable ads for any company, but especially for #healthcare or #eyecare, is there typically a #memorable starring:
0 · Reply